STOCK TITAN

Omeros posts $57.4M Q3 2026 net loss as revenue rises

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Omeros Corporation (OMER) reported third-quarter 2026 YARTEMLEA gross revenue of $41.8 million and net revenue of $35.9 million, compared with $32.2 million and $28.5 million, respectively, in the second quarter. GAAP net loss was $57.4 million, or $0.79 per share, including a $62.0 million non-cash loss primarily from mark-to-market adjustments on the 2029 Notes derivative; non-GAAP adjusted net income was $4.7 million, or $0.06 per share.

Cash and short-term investments were $95.3 million as of September 30, 2026, and operating cash flow was $13.3 million for the quarter. Omeros repurchased $30.5 million aggregate principal amount of 2029 Notes in transactions that closed in July 2026, for $60.2 million plus $0.2 million accrued and unpaid interest. Approximately $40.3 million principal remained outstanding, and the repurchases eliminated $8.6 million in scheduled interest payments. NTAP reimbursement took effect October 1, 2026, allowing eligible hospitals up to $287,079 per eligible YARTEMLEA inpatient case.

In October 2026, the EMA’s Committee for Medicinal Products for Human Use issued a negative opinion on narsoplimab’s TA-TMA marketing authorization application after re-examining its original negative opinion adopted in June 2026. Omeros expects OMS527 enrollment to begin in the first quarter of 2027 while conducting additional nonclinical work requested by the FDA.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

How the balance works

Positive

  • Moderate pointYARTEMLEA net revenue rose 26% sequentially to $35.9 million.
  • Moderate pointOperating income reached $4.5 million, versus a $26.4 million loss a year earlier.

Negative

  • Major pointEMA’s CHMP issued a negative opinion on the narsoplimab TA-TMA application.
  • Moderate pointGAAP net loss was $57.4 million, versus $13.2 million net income in Q2.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
YARTEMLEA gross revenue $41.8 million Third quarter 2026; $32.2 million in the second quarter
YARTEMLEA net revenue $35.9 million Third quarter 2026; up 26% from $28.5 million in the second quarter
GAAP net loss $57.4 million; $0.79 per share Third quarter 2026
Non-GAAP adjusted net income $4.7 million; $0.06 per share Third quarter 2026
Cash and short-term investments $95.3 million As of September 30, 2026
Operating cash flow $13.3 million Third quarter 2026
2029 Notes principal repurchased $30.5 million Repurchased for $60.2 million plus $0.2 million accrued and unpaid interest
NTAP reimbursement Up to $287,079 per eligible inpatient case Additional Medicare reimbursement for eligible hospitals treating patients with YARTEMLEA; effective October 1, 2026
thrombotic microangiopathy medical
"stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”)"
Thrombotic microangiopathy is a medical condition where tiny blood clots form inside the smallest blood vessels, blocking flow and damaging organs such as the kidneys and brain. Investors should care because TMA can be a serious safety signal in clinical trials or post-market reports, trigger regulatory action or product recalls, and create liability or revenue risk for companies developing or selling related therapies—think of it as microscopic plumbing clogs that can shut down vital systems.
340B Drug Pricing Program regulatory
"entities covered by the 340B Drug Pricing Program"
A federal program that lets eligible hospitals and clinics buy outpatient prescription drugs at significant discounts, similar to a store offering bulk-price deals to certain shoppers. It matters to investors because those discounts affect how much drugmakers can charge, influence hospitals’ medication costs and margins, and shape pricing and reimbursement dynamics across the healthcare market, which can change revenue and profit forecasts.
gross-to-net adjustment financial
"third-quarter gross-to-net adjustment was 14.0%"
mark-to-market adjustments financial
"primarily related to mark-to-market adjustments of a derivative"
Mark-to-market adjustments are updates companies make to the value of assets or liabilities to reflect their current market price, like re-pricing items in a garage sale to match what buyers would pay today. For investors, these adjustments matter because they can change reported profits and the size of a company’s balance sheet quickly, revealing real-time gains, losses and the true risk exposure of holdings.
New Technology Add-on Payment regulatory
"The New Technology Add-on Payment (NTAP) status for YARTEMLEA became effective"
A new technology add-on payment is a temporary extra reimbursement that Medicare gives hospitals for genuinely new, high-cost medical devices, drugs or procedures that aren’t yet fully covered by standard hospital payments. It matters to investors because this top-up helps hospitals afford and adopt costly innovations—similar to a short-term subsidy—boosting revenue prospects for device makers and speeding market uptake, which can affect sales, valuation, and adoption timelines.
MASP-2 medical
"our long-acting antibody targeting MASP-2"
MASP-2 is an enzyme that helps trigger the complement system, a rapid part of the immune response that marks and removes pathogens and damaged cells. Because it acts like a fuse in an inflammatory sprinkler system, drugs that block MASP-2 can reduce harmful inflammation in diseases driven by complement overactivity, making it a meaningful drug target whose clinical progress can influence biotech valuations and investment decisions.
YARTEMLEA gross revenue $41.8 million 29.6% increase from $32.2 million in the second quarter of 2026
YARTEMLEA net revenue $35.9 million 26% increase from $28.5 million in the second quarter of 2026
GAAP net loss $57.4 million; $0.79 per share Compared with $13.2 million net income, or $0.18 per share, in the second quarter of 2026
Non-GAAP adjusted net income $4.7 million; $0.06 per share Compared with $1.8 million, or $0.02 per share, in the second quarter of 2026
Cash and short-term investments $95.3 million As of September 30, 2026
Operating cash flow $13.3 million Generated in the third quarter of 2026
Operating income $4.5 million Compared with $0.1 million in the second quarter of 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did OMER report for YARTEMLEA in Q3 2026?

YARTEMLEA generated $41.8 million in gross revenue and $35.9 million in net revenue in the third quarter of 2026. The second-quarter figures were $32.2 million and $28.5 million, respectively; net revenue increased 26% sequentially.

Why did OMER report a GAAP net loss in Q3 2026?

Omeros recorded a $57.4 million GAAP net loss, including a $62.0 million non-cash loss primarily from mark-to-market adjustments on a derivative associated with the 2029 Notes. Excluding non-cash fair-value remeasurement, non-GAAP adjusted net income was $4.7 million.

How much of the 2029 Notes did OMER repurchase?

Omeros repurchased $30.5 million aggregate principal amount of the 2029 Notes for $60.2 million, plus $0.2 million accrued and unpaid interest. The transactions closed in July 2026, leaving approximately $40.3 million principal outstanding and eliminating $8.6 million in scheduled interest payments.

What did the European regulator decide about OMER’s narsoplimab application?

In October 2026, the EMA’s Committee for Medicinal Products for Human Use issued a negative opinion on the narsoplimab marketing authorization application for TA-TMA, after re-examining its original negative opinion adopted in June 2026.

When does OMER expect OMS527 enrollment to begin?

Omeros expects enrollment to begin in the first quarter of 2027. The company is conducting a nonclinical study to address the FDA’s request for additional nonclinical information before initiating the inpatient clinical trial.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001285819 0001285819 2026-11-16 2026-11-16
 


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 16, 2026

 
OMEROS CORPORATION
(Exact name of Registrant as Specified in Its Charter)
 

 
Washington
001-34475
91-1663741
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
     
201 Elliott Avenue West
Seattle, WA
 
98119
(Address of Principal Executive Offices)
 
(Zip Code)
 
Registrant’s Telephone Number, Including Area Code: (206) 676-5000
 
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities Registered Pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, $0.01 par value per share
OMER
The Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).         
Emerging growth company  ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 


 
 

 
Item 2.02 Results of Operations and Financial Condition.
 
On November 16, 2026, Omeros Corporation issued a press release announcing financial results for the three and nine months ended September 30, 2026. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
 
The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit, including any information contained on or accessible through any website reference in the exhibit shall not be incorporated by reference into any filing with the United States Securities and Exchange Commission made by Omeros Corporation, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The inclusion of any website address in this Current Report on Form 8-K by incorporation by reference of the press release is as an inactive textual reference only.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit
Number
 
Description
     
99.1
 
Press release, dated November 16, 2026, pertaining to Omeros Corporation's financial results for the three and nine months ended September 30, 2026
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
 
OMEROS CORPORATION
     
Date: November 16, 2026
By:
/s/ Gregory A. Demopulos
   
Gregory A. Demopulos, M.D.
   
President, Chief Executive Officer and
   
Chairman of the Board of Directors
 
 

Exhibit 99.1

logo.jpg

 

 

Omeros Corporation Reports Third Quarter 2026 Financial Results

 

– Conference Call Today at 4:30 p.m. ET

 

 

SEATTLE, WA – November 16, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2026, which include:

 

Third Quarter and Recent Highlights

 

●     YARTEMLEA® (narsoplimab-wuug), the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”), an often-lethal complication of stem cell transplantation, generated gross revenue of $41.8 million in the third quarter of 2026, an increase of 30% from $32.2 million in the second quarter. Net revenue increased 26% to $35.9 million from $28.5 million in the second quarter. The third-quarter gross-to-net adjustment was 14.0% compared to 11.5% in the prior quarter.

 

●     GAAP net loss for the third quarter of 2026 was $57.4 million, or $0.79 per share, including a non-cash loss of $62.0 million primarily related to mark-to-market adjustments of a derivative associated with our unsecured convertible notes due 2029 (the “2029 Notes”). This compares with GAAP net income of $13.2 million, or $0.18 per share, for the second quarter, which included a non-cash gain of $11.5 million primarily related to the same mark-to-market adjustments.

 

●     Excluding these non-cash items, non-GAAP adjusted net income for the third quarter of 2026 was $4.7 million, or $0.06 per share, compared with $1.8 million, or $0.02 per share, for the second quarter.

 

●     At September 30, 2026, we had $95.3 million of cash and short-term investments. We generated positive operating cash flow of $13.3 million in the third quarter of 2026.

 

●     In June and July 2026, we entered into privately negotiated agreements to repurchase $30.5 million aggregate principal amount of the 2029 Notes for a total purchase price of $60.2 million, plus accrued and unpaid interest of $0.2 million. Both transactions closed in July 2026, leaving approximately $40.3 million aggregate principal amount of the 2029 Notes outstanding. The repurchases reduced the aggregate number of shares issuable on conversion of the 2029 Notes by approximately 4.9 million, from 11.4 million to 6.5 million, and eliminated $8.6 million in scheduled interest payments. Together with our repurchase of more than 843,000 shares of common stock at $11.70 per share during the first half of 2026, these transactions reduced the number of outstanding or potentially issuable shares by approximately 5.8 million year to date.

 

●     In October 2026, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on our marketing authorization application (MAA) for narsoplimab in TA-TMA following re-examination of its original negative opinion adopted in June 2026.

 

“YARTEMLEA sales continued to grow during the third quarter, delivering consecutive quarters of positive operating cash flow,” said Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer. “As expected, 340B participation increased, reflecting substantial expansion of our customer base and increased outpatient use of YARTEMLEA. That momentum has continued into the fourth quarter, with YARTEMLEA revenues continuing to grow. We are investing in field education to make earlier recognition of TA-TMA and timely treatment with YARTEMLEA part of everyday transplant care. We are also working to expand TA-TMA patient access through international regulatory approvals and named-patient programs. In the U.S., we are helping transplant centers understand YARTEMLEA’s reimbursement advantages, including additional Medicare inpatient payments under NTAP, effective October 1, and favorable Medicare outpatient reimbursement for 340B-acquired YARTEMLEA beginning January 1, 2027.”

 

“We see YARTEMLEA not simply as a TA-TMA drug, but as an endothelial injury drug with broad therapeutic potential. YARTEMLEA revenues are funding our efforts to expand its indications, with clinical studies expected to begin soon in ARDS and TA-TMA prevention, and to initiate the Phase 2 clinical program for our long-acting MASP-2 inhibitor OMS1029. Together with expected zaltenibart-related milestone payments from Novo, these revenues are driving the rest of our pipeline forward: the OMS527 Phase 2 trial in cocaine use disorder planned to start early next year; the OncotoX-AML Phase 1b trial slated for late 2027; T-CAT, now in IND-enabling studies; and oral MASP-2 and MASP-3 inhibitors advancing toward the clinic. Across these first-in-class programs, as with YARTEMLEA, our objective remains to improve outcomes and save patients’ lives.”

 

 

Recent Developments

 

●     YARTEMLEA and our broader MASP-2 inhibitor platform

 

○       In September 2026, the National Organization for Rare Disorders (“NORD”), the nation’s leading rare disease patient advocacy organization, named Omeros a recipient of its 2026 Industry Innovation Award for YARTEMLEA. In announcing the award, NORD stated that bone marrow transplant advocacy groups and medical institutions specializing in the procedure have lauded the approval of YARTEMLEA as a targeted and potentially life-saving therapy.

 

○       On October 1, 2026, the New Technology Add-on Payment (“NTAP”) status for YARTEMLEA became effective. The NTAP designation provides eligible hospitals with up to $287,079 in additional Medicare reimbursement per eligible inpatient case involving YARTEMLEA and is expected to reduce hospitals’ net treatment costs and support patient access. No off-label treatment for TA-TMA, whether branded or biosimilar, has an NTAP.

 

○       Added 10 field-based education positions across our Market Development Manager and Medical Science Liaison teams and a new clinical nurse educator team. The six nurse educators, recruited from top-tier transplant centers, will train transplant nursing teams nationwide to support earlier recognition of TA-TMA and timely treatment with YARTEMLEA.

 

○       We expect to support two investigator-initiated and/or Omeros co-sponsored studies evaluating YARTEMLEA: one in hyperinflammatory acute respiratory distress syndrome (“ARDS”) and the other in the prevention of TA-TMA in high-risk pediatric transplant patients. Both are designed as open-label, single-arm studies with historical controls, with target enrollment of approximately 50 to 60 patients each. Study initiation is anticipated in late 2026 or early 2027, subject to institutional review board and ethics committee approvals.

 

○       We are also assessing further development opportunities for YARTEMLEA in other indications involving endothelial injury, lectin pathway activation, or thrombo-inflammation, including stem cell transplant-related endothelial syndromes such as graft-versus-host disease, sinusoidal obstruction syndrome, capillary leak syndromes, and diffuse alveolar hemorrhage. Endothelial injury and lectin pathway activation are considered central to the pathology of solid organ transplant-related TMA, chemotherapy-induced TMA, sickle cell disease, acute kidney injury, and delayed graft function.

 

○       In parallel, we are finalizing the initial indication for a Phase 2 clinical program for OMS1029, our long-acting antibody targeting MASP-2. In our MASP-2 small-molecule inhibitor program, we continue characterizing compounds to select an oral development candidate.

 

●     Novo collaboration and MASP-3 inhibitor platform

 

○       Novo is developing zaltenibart, the MASP-3 inhibitor antibody it acquired from Omeros in 2025 and is on track for Phase 3 trial initiation. Under the terms of the transaction, we remain eligible to receive more than $1.8 billion in development and commercial milestones, including up to $100 million in near-term milestone payments, plus tiered royalties on net sales. We continue to provide transition services at Novo’s cost and expect to complete those services by mid-2027.

 

○       We continue to advance our MASP-3 small-molecule inhibitor program toward the clinic.

 

●     OMS527 for the treatment of addiction — cocaine use disorder program funded by the National Institute on Drug Abuse (“NIDA”)

 

○       We are developing, at NIDA’s request, our lead orally administered phosphodiesterase 7 (“PDE7”) inhibitor for the treatment of cocaine use disorder. Preclinical studies, designed with NIDA toxicologists, were completed and identified no drug-interaction or safety concerns, supporting the scheduled inpatient human clinical trial of OMS527 in cocaine users.

 

○       We are conducting a nonclinical study to address FDA’s request for additional nonclinical information before initiating the inpatient clinical trial. We expect to begin enrollment in the first quarter of 2027. 

 

●     Oncology platform — OncotoX-AML/OMS805

 

○       We continue to develop our OncotoX-AML/OMS805 program targeting acute myeloid leukemia (“AML”), an aggressive and highly fatal bone marrow and blood cancer.

 

○       A first-in-human Phase 1b clinical trial evaluating OMS805, the lead drug development candidate in our OncotoX-AML program, is targeted to begin in late 2027. IND-enabling studies and manufacturing development activities for the initial clinical supply of OMS805 drug substance are underway.

 

○       Across tumor-bearing animal models and in vitro human AML cell-line studies, OMS805 demonstrated efficacy superior to current AML standard-of-care treatments evaluated. This efficacy was independent of AML-related genetic mutations, including TP53, NPM1, KMT2A, and FLT3, collectively found in approximately 90% of AML patients.

 

○       In February 2026, we announced the successful completion of our initial study in nonhuman primates evaluating the efficacy and safety of OncotoX-AML. Administration of only one course of OncotoX-AML treatment to immunocompetent primates produced the desired pharmacologic response, selectively and reversibly reducing myeloid progenitor cells by up to 99%. OncotoX-AML was well tolerated, with preservation of hematopoietic stem cells. There were no observed safety signals or meaningful changes in blood chemistry values.

 

●     Targeted Complement Activating Therapy (“T-CAT”) platform

 

○       Our T-CAT platform uses a new class of recombinant antibodies designed to target and directly kill pathogens, including bacteria, fungi, viruses, and parasites, by activating complement locally on pathogen surfaces. Our T-CAT antibodies are expected to treat infections caused by drug-resistant organisms without enhancing drug resistance. We are initially focused on treating infections caused by multidrug-resistant organisms (“MDROs”), one of the most critical unmet needs in medicine.

 

Financial Results

 

YARTEMLEA gross revenue was $41.8 million during the third quarter of 2026, an increase of $9.5 million, or 29.6%, from gross revenue of $32.2 million in the second quarter of 2026. Net revenue increased 26% to $35.9 million from $28.5 million in the second quarter. The third-quarter gross-to-net adjustment was 14.0%, compared to 11.5% in the second quarter. This increase in gross-to-net adjustment was driven by higher purchases by entities covered by the 340B Drug Pricing Program, consistent with our goals of increasing outpatient utilization of YARTEMLEA and expanding our customer base.

 

GAAP net loss for the third quarter of 2026 was $57.4 million, or $0.79 per share, including a non-cash loss of $62.0 million primarily related to mark-to-market adjustments of a derivative associated with our 2029 Notes. This compares with GAAP net income of $13.2 million, or $0.18 per share, for the second quarter, which included a non-cash gain of $11.4 million primarily related to the same mark-to-market adjustments.

 

Excluding these non-cash items, non-GAAP adjusted net income for the third quarter of 2026 was $4.7 million, or $0.06 per share, compared with $1.8 million, or $0.02 per share, for the second quarter.

 

At September 30, 2026, we had $95.3 million of cash and short-term investments. We generated positive operating cash flow of $13.3 million in the third quarter of 2026.

 

In June and July 2026, we entered into privately negotiated agreements with certain holders of the 2029 Notes under which we agreed to repurchase $30.5 million aggregate principal amount of the 2029 Notes for a total purchase price of $60.2 million, plus accrued and unpaid interest of $0.2 million. Both transactions closed in July 2026, leaving approximately $40.3 million aggregate principal amount of the 2029 Notes outstanding. In addition to eliminating approximately $8.6 million in future interest payment obligations, the repurchases reduced the aggregate number of shares issuable on conversion of the 2029 Notes by 4.9 million shares. Together with our repurchase of more than 843,000 shares of common stock at a volume-weighted average price of $11.70 per share during the first half of 2026, these transactions reduced the number of outstanding or potentially issuable shares by 5.8 million year to date.

 

Research and development and selling, general and administrative expenses totaled approximately $30.6 million in the third quarter, compared with $27.7 million in the second quarter. We reported operating income of $4.5 million for the third quarter compared with $0.1 million for the second quarter.

 

Interest and other income were $1.9 million for the third quarter of 2026, compared to $4.6 million during the second quarter of 2026. The $2.7 million decrease was primarily the result of a reimbursement from Novo for the transfer of zaltenibart inventory recorded in the second quarter. 

 

Conference Call Details

 

Omeros’ management will host a conference call and webcast to discuss these financial results and to provide an update on business activities. The call will be held today at 1:30 p.m. Pacific Time; 4:30 p.m. Eastern Time.

 

To access the live webcast, register at https://events.q4inc.com/attendee/283590793 or visit Omeros’ website at https://investor.omeros.com/upcoming-events.

 

A replay of the call will be available online for 90 days at https://investor.omeros.com/archived-events.

 

About Omeros Corporation

 

Omeros is an innovative biotechnology company that discovers, develops, and commercializes first-in-class protein and small-molecule therapeutics for both large-market and orphan indications, with a focus on the treatment of complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros’ lead complement inhibitor YARTEMLEA® (narsoplimab-wuug), which targets the lectin pathway’s effector enzyme MASP-2, is FDA-approved and commercially available in the U.S. for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients two years of age and older. OMS1029, Omeros’ long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials.

 

Under an asset purchase and licensing agreement, Novo acquired global rights to zaltenibart (formerly OMS906) and associated intellectual property and related assets. Zaltenibart is an inhibitor of MASP-3, the alternative pathway’s key activator, and is in clinical development for paroxysmal nocturnal hemoglobinuria (PNH) and other diseases mediated by the alternative pathway. Omeros’ pipeline also includes OMS527, a phosphodiesterase 7 inhibitor in clinical development for cocaine use disorder. Development of OMS527 for this indication is fully funded by the National Institute on Drug Abuse. Omeros is also advancing a growing portfolio of novel recombinant antibodies targeting multidrug-resistant organisms and novel molecular and cellular therapeutic programs for oncology. For more information about Omeros and its programs, visit www.omeros.com. 

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the “safe harbor” created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “likely,” “look forward to,” “may,” “objective,” “plan,” “potential,” “predict,” “project,” “should,” “slate,” “target,” “will,” “would,” and similar expressions and variations thereof. Forward-looking statements, including statements regarding the anticipated therapeutic benefits of drug candidates within our development pipeline, plans and expectations regarding the commercial launch of YARTEMLEA® in the U.S., our expectations regarding the utility of the NTAP, our expectations regarding development of zaltenibart, our ability to consummate licensing, partnering or other transactions and the benefits, if any, we would receive from any such transactions, expectations regarding the sufficiency and availability of our capital resources to fund current and planned operations, including the commercialization of YARTEMLEA, are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros’ actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, unfavorable or unexpected regulatory conclusions or interpretations related to the clinical data, external registry data, statistical analyses or other information and data included in our marketing authorization application or our inability to respond satisfactorily to information requests during regulatory review, unanticipated or unexpected outcomes or requirements of regulatory processes in relevant jurisdictions, our financial condition and results of operations, including our ability to raise additional capital for our operations or complete other transactions on favorable terms or at all, regulatory processes and oversight, challenges associated with manufacture or supply of our products to support clinical trials, regulatory inspections and/or commercial sale following any marketing approval, changes in reimbursement and payment policies by government and commercial payers or the application of such policies, intellectual property claims, competitive developments, litigation, and the risks, uncertainties, and other factors described under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026 and in our subsequently filed Quarterly Reports on Form 10-Q. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

 

Non-GAAP Financial Measures

 

This press release includes financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). A non-GAAP financial measure is generally defined as one that purports to measure historical or future financial position, results of operations or cash flows but excludes or includes amounts that would not be included in most GAAP measures. We define non-GAAP adjusted net income (loss) as GAAP net income (loss) adjusted to exclude the non-cash remeasurement of the fair value of financial instruments.  We believe non-GAAP adjusted net income (loss) to be a more accurate measure in evaluating the Company’s performance because it excludes the fluctuations in the fair value of Omeros’ embedded derivatives. This is not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with Omeros’ financial statements prepared in accordance with GAAP. These non-GAAP measures differ from GAAP measures with the same captions, may be different from non-GAAP financial measures with the same or similar captions that are used by other companies, and do not reflect a comprehensive system of accounting.

 

 

Contact:

 

 

Jennifer Cook Williams

Cook Williams Communications, Inc.

Investor and Media Relations

IR@omeros.com

 

 

 

OMEROS CORPORATION

 

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

 

(In thousands, except share and per share data)

 

 

   

Three Months Ended

   

Nine Months Ended

 
   

September 30,

   

September 30,

 
   

2026

   

2025

   

2026

   

2025

 

Product sales, net

  $ 35,934     $ —     $ 74,356     $ —  
                                 

Costs and expenses:

                           

Cost of product sales

    826       —       2,211       —  

Research and development

    16,060       15,995       43,216       61,850  

Selling, general and administrative

    14,547       10,397       41,775       31,865  

Total costs and expenses

    31,433       26,392       87,202       93,715  

Income (loss) from operations

    4,501       (26,392 )     (12,846 )     (93,715 )

Interest and other income

    1,867       616       7,968       2,979  

Interest expense, net of remeasurement adjustments and other

    (6,222 )     13,355       (19,701 )     9,686  

Net gain (loss) on change in fair value of financial instruments

    (62,020 )     (8,822 )     22,573       (680 )

Loss on early extinguishment of 2029 Notes

    (1,905 )     —       (3,801 )     —  

Loss on early extinguishment of 2026 Notes

    —       —       —       (2,968 )

Loss from continuing operations before income tax expense

    (63,779 )     (21,243 )     (5,807 )     (84,698 )

Income tax expense

    (46 )     —       (132 )     —  

Net loss from continuing operations

    (63,825 )     (21,243 )     (5,939 )     (84,698 )

Net income (loss) from discontinued operations, net of tax

    6,469       (9,674 )     17,875       (5,103 )

Net income (loss)

  $ (57,356 )   $ (30,917 )   $ 11,936     $ (89,801 )
                         

Basic net income (loss) per share:

                       

Net loss from continuing operations

  $ (0.88 )   $ (0.32 )   $ (0.09 )   $ (1.39 )

Net income (loss) from discontinued operations

    0.09       (0.15 )     0.25       (0.08 )

Net income (loss)

  $ (0.79 )   $ (0.47 )   $ 0.16     $ (1.47 )
                         

Diluted net income (loss) per share:

                       

Net loss from continuing operations

  $ (0.87 )   $ (0.32 )   $ (0.07 )   $ (1.39 )

Net income (loss) from discontinued operations

    0.09       (0.15 )     0.20       (0.08 )

Net income (loss)

  $ (0.79 )   $ (0.47 )   $ 0.13     $ (1.47 )
                         

Weighted-average shares used in per share computation:

                               

Basic

    72,981,654       66,263,992       72,349,533       61,049,886  

Diluted

    72,981,654       66,263,992       88,864,266       61,049,886  

 

 

 

 

OMEROS CORPORATION

 

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

 

(In thousands)

 

   

September 30,

   

December 31,

 
   

2026

   

2025

 

Assets

           

Current assets:

           

Cash and cash equivalents

  $ 5,070     $ 9,660  

Short-term investments

    90,180       162,144  

OMIDRIA contract royalty asset, short-term

    25,730       25,351  

Receivables

    23,096       10,917  

Inventory

    66       —  

Prepaid expense and other assets

    6,751       7,595  

Total current assets

    150,893       215,667  

OMIDRIA contract royalty asset

    87,897       96,435  

Right of use assets

    7,004       10,708  

Property and equipment, net

    1,247       1,768  

Restricted investments

    1,054       1,054  

Total assets

  $ 248,095     $ 325,632  
             

Liabilities and shareholders’ deficit

               

Current liabilities:

               

Accounts payable

  $ 4,902     $ 4,764  

Accrued expenses

    32,532       29,388  

OMIDRIA royalty obligation

    22,338       20,547  

2026 Notes, net

    —       17,063  

Lease liabilities

    6,798       6,300  

Total current liabilities

    66,570       78,062  

OMIDRIA royalty obligation, non-current

    130,624       147,319  

2029 Notes, non-current, net

    31,891       51,364  

2029 Notes embedded derivative, non-current

    101,136       157,171  

Lease liabilities, non-current

    2,145       7,245  

Other accrued liabilities, non-current

    5,702       5,702  

Shareholders’ deficit:

               

Common stock and additional paid-in capital

    811,786       792,464  

Accumulated deficit

    (901,759 )     (913,695 )

Total shareholders’ deficit

    (89,973 )     (121,231 )

Total liabilities and shareholders’ deficit

  $ 248,095     $ 325,632  

 

 

 

OMEROS CORPORATION

 

UNAUDITED SCHEDULE OF INTEREST EXPENSE, NET OF REMEASUREMENT ADJUSTMENTS AND OTHER

 

(In thousands)

 

   

Three Months Ended

   

Nine Months Ended

 
   

September 30,

   

September 30,

 
   

2026

   

2025

   

2026

   

2025

 
   

(In thousands)

 

OMIDRIA royalty obligation

                               

Pass through interest remitted to administrative agent

  $ 3,771     $ 4,759       11,670       15,045  

Non-cash remeasurement adjustment

    477       (22,292 )     (376 )     (34,170 )

Interest expense, net of remeasurement on OMIDRIA royalty obligation

    4,248       (17,533 )     11,294       (19,125 )
                                 

2029 Notes

                               

Contractual interest expense

    1,059       1,682       4,421       2,541  

Amortization of debt discount and issuance costs

    901       1,458       3,784       2,206  

Interest expense on 2029 Notes

    1,960       3,140       8,205       4,747  
                                 

2026 Notes

                               

Contractual interest expense

    —       248       112       2,323  

Amortization of debt discount and issuance costs

    —       20       14       260  

Interest expense on 2026 Notes

    —       268       126       2,583  
                                 

Term Loan

                               

Contractual interest expense

    —       2,258       —       6,723  

Amortization of debt premium and issuance costs

    —       (1,512 )     —       (4,727 )

Interest expense on Term Loan

    —       746       —       1,996  
                                 

Finance leases and other

    14       24       76       113  
                                 

Total interest expense, net of remeasurement adjustments and other

  $ 6,222     $ (13,355 )   $ 19,701     $ (9,686 )

 

 

 

 

OMEROS CORPORATION

 

UNAUDITED THREE AND NINE MONTHS GAAP TO NON-GAAP RECONCILIATION

 

(In thousands)

 

   

Three Months Ended

   

Nine Months Ended

 
   

September 30,

   

September 30,

 
   

2026

   

2025

   

2026

   

2025

 

Reconciliation of GAAP net income (loss) to Non-GAAP adjusted net income (loss)

                               
                                 

Numerator (in thousands)

                               

Net income (loss)

  $ (57,356 )   $ (30,917 )   $ 11,936     $ (89,801 )

Less: remeasurement of fair value of financial instruments

    62,020       8,822       (22,573 )     680  
                                 

Non-GAAP adjusted net income (loss)

  $ 4,664     $ (22,095 )   $ (10,637 )   $ (89,121 )
                                 

Denominator (in shares)

                               

Basic weighted average shares

    72,981,654       66,263,992       72,349,533       61,049,886  
                                 

Net income (loss) per share basic

  $ (0.79 )   $ (0.47 )   $ 0.16     $ (1.47 )
                                 

Non-GAAP adjusted net income (loss) per share basic

  $ 0.06     $ (0.33 )   $ (0.15 )   $ (1.46 )

 

 

 

OMEROS CORPORATION

 

UNAUDITED SEQUENTIAL GAAP TO NON-GAAP RECONCILIATION

 

(In thousands)

 

 

 

   

Three Months Ended

 
   

March 31,

   

June 30,

   

September 30,

 
   

2026

   

2026

   

2026

 

Reconciliation of GAAP net income (loss) to Non-GAAP adjusted net income (loss)

                       
                         

Numerator (in thousands)

                       

Net income (loss)

  $ 56,060     $ 13,232     $ (57,356 )

Less: remeasurement of fair value of financial instruments

    (73,146 )     (11,447 )     62,020  
                         

Non-GAAP adjusted net income (loss)

  $ (17,086 )   $ 1,785     $ 4,664  
                         

Denominator (in shares)

                       

Basic weighted average shares

    71,917,180       72,131,526       72,981,654  
                         

Net income (loss) per share basic

  $ 0.78     $ 0.18     $ (0.79 )
                         

Non-GAAP adjusted net income (loss) per share basic

  $ (0.24 )   $ 0.02     $ 0.06  

 

 

 

 

Filing Exhibits & Attachments

5 documents

Keep reading